Darvadstrocel

N/A

Report date: 2023/01/12 15:47:56

Base Information

Drug NameDarvadstrocel
Drug Alias NameeASC therapy脂肪源性异基因干细胞治疗 - TiGenix脂肪来源的同种异体干细胞疗法 - TiGenixAlofiselCX-601
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapyCell and gene therapy > Cell therapy > Source of cells > Adipose-derived
Mechanisms of ActionCell replacementsImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsCrohn DiseaseRectal Fistula
Global Approved IndicationsRectal Fistula
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2018/03/23
Country/TerritoryCzechiaBelgiumCanada +[19] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesTigenix Nv
China Registration ClassN/A

Develop Information

Active CompaniesTakeda Pharmaceutical Co LtdTakeda Pharma A/STigenix Sau
Inactive CompaniesTakeda Development Center Americas Inc
Active IndicationsCrohn DiseaseRectal Fistula
Inactive IndicationsN/A

Other Information

ATC CodeL04A
Related LinksN/A